Model Medicines to Participate in Upcoming TSX Investor Event

As an innovative AI-driven drug discovery company, we look forward to exploring opportunities to connect with Canadian investors and capital markets through this premier event.

The TSX and TSXV are leading global exchanges that provide an excellent platform for growth-stage biotech companies like Model Medicines. With strategic relationships across key U.S. markets and a streamlined listing process, they enable access to knowledgeable investors receptive to emerging technologies.

Joined by Gowling WLG, DuMoulin Black, Davidson & Company, and The Consulate General of Canada, Model Medicines aims to build an understanding of the financing options and support available through TSX and TSXV. We are eager to evaluate if these markets could be the right fit as Model advances its pipeline of AI-discovered therapeutics.

"TSX provides an invaluable forum to connect with Canadian dealmakers and advisors experienced in helping U.S. companies access growth capital," noted Daniel Haders, CEO of Model Medicines. "We appreciate the chance to showcase our GALILEO platform and explore novel funding avenues as we work to scale our business and accelerate the path to new cures."